Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

9342-8530 Quebec Inc DGCRF

Diagnocure Inc is a Canada based biotechnology company. It is primarily engaged in the business activity of development and commercialization of products relating to the diagnosis of cancer. The group generates its revenue from research and license agreement. The head office of the company is located in Quebec, Canada.


GREY:DGCRF - Post by User

Post by Konderoon Sep 12, 2012 9:53pm
146 Views
Post# 20354827

clause of the agreement ?

clause of the agreement ?

I was wondering why Signal acted deliberately and with so much assurance. Is it possible because a clause of the agreement with CUR has not been fulfilled ? The one that stipulating that no numbers about the royalties should not be disclosed ?

I remember that a member of CUR staff publicly insinuated ( in  letting fall a hint ) that it was 8 %. At least, everybody understood it was 8 %. It happened 6 or 7 months ago. Anyway , Signal Genetics would have took advantage of that pretext to  act as they did.

This is just speculation.

Fantomatus

<< Previous
Bullboard Posts
Next >>